Finally, in the future, by screening small molecule compounds or peptide inhibitors targeting key residues of VAMP2 (e.g., Arg56 and Lys59) or stabilizing the SNARE complex, we may evaluate their ameliorative effects on synaptic functions and AD pathological processes in cellular and animal models. The gene discussed is VAMP2; the disease is Alzheimer disease.